The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. (Q38096241)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

low-grade serous carcinoma

28 February 2020

main subject

1 reference

high-grade serous carcinoma

inferred from title

0 references

author

Martin Köbel

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Alon D Altman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Gregg Nelson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Prafull Ghatage

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

John B McIntyre

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Pamela Chu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jill G Nation

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Anthony N Karnezis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Guangming Han

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Steve E Kalloger

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

David Capper

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

5 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1255-1263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/modpathol.2013.55

28 February 2020

exact match

0 references

cites work

Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Diverse tumorigenic pathways in ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Critical molecular abnormalities in high-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Ovarian low-grade serous carcinoma: a comprehensive update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Calculator for ovarian carcinoma subtype prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Architectural patterns of ovarian/pelvic high-grade serous carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Loss of p16INK4A expression in low-grade ovarian serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Low-grade serous carcinomas of the ovary contain very few point mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer: primary or interval debulking?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Low-grade serous ovarian cancer: a unique disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

7 January 2021

Grading ovarian serous carcinoma using a two-tier system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

7 January 2021

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

7 January 2021

Low-grade serous primary peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

7 January 2021

Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

7 January 2021

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

7 January 2021

Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.55

7 January 2021

10.1038/MODPATHOL.2013.55

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

28 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23558569%20AND%20SRC:MED&resulttype=core&format=json